Praluent ICD-10 Pocket Guide

Table of contents

Section 1

Section 2

A guide to ICD-10-CM coding for patients who are prescribed PRALUENT for an indication approved by the US Food and Drug Administration

PRALUENT

ICD-10-CM pocket guide

The coding information discussed in this document is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed herein may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

Indications and Usage PRALUENT is indicated: ? to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with

established cardiovascular disease. ? as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering

therapies in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C. ? as an adjunct to other LDL-C-lowering therapies in adults with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. Important Safety Information PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any of the excipients in PRALUENT. Hypersensitivity reactions, including hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Section 3

Section 4

Table of contents

Section 1

Section 1

Section 2

Section 2

Section 4 Section 3

2

Table of contents

Primary and secondary ICD-10-CM codes

Disorders of lipoprotein metabolism and other lipidemias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Transient cerebral ischemic attacks and related syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Ischemic heart diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Angina pectoris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Other acute ischemic heart diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Chronic ischemic heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Cerebrovascular diseases.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Cerebral infarction.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Other cerebrovascular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Diseases of arteries, arterioles, and capillaries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Atherosclerosis.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Other peripheral vascular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Family history of other specific disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Presence of cardiac and vascular implants and grafts .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Other postprocedural states . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

Please use as many secondary codes as needed to appropriately describe your patient's condition.

Need additional support?

Visit



OR

Call

1-844-PRALUENT (1-844-772-5836), Monday?Friday, 8 AM?8 PM Eastern time

Brought to you by Regeneron Pharmaceuticals, Inc. Please see Important Safety Information throughout and click here for full Prescribing Information.

Section 3

Section 4

Table of contents

Disorders of lipoprotein metabolism and other lipidemias,

3

1

transient cerebral ischemic attacks and related syndromes, and ischemic heart diseases

Section 1

Section 2

E78: Disorders of lipoprotein metabolism and other lipidemias E78.0 Pure hypercholesterolemia E78.00 Pure hypercholesterolemia, unspecified E78.01 Familial hypercholesterolemia E78.2 Mixed hyperlipidemia E78.4 Other hyperlipidemia E78.5 Hyperlipidemia, unspecified

G45: Transient cerebral ischemic attacks and related syndromes G45.0 Vertebro-basilar artery syndrome G45.1 Carotid artery syndrome (hemispheric) G45.2 Multiple and bilateral precerebral artery syndromes G45.8 Other transient cerebral ischemic attacks and related syndromes G45.9 Transient cerebral ischemic attack, unspecified

Ischemic heart diseases

I20: Angina pectoris I20.0 Unstable angina I20.1 Angina pectoris with documented spasm I20.8 Other forms of angina pectoris I20.9 Angina pectoris, unspecified

I21: Acute myocardial infarction I21.0 ST elevation (STEMI) myocardial infarction of anterior wall I21.01 ST elevation (STEMI) myocardial infarction involving left main coronary artery I21.02 ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery I21.09 ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall I21.1 ST elevation (STEMI) myocardial infarction of inferior wall I21.11 ST elevation (STEMI) myocardial infarction involving right coronary artery I21.19 ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall I21.2 ST elevation (STEMI) myocardial infarction of other sites I21.21 ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery I21.29 ST elevation (STEMI) myocardial infarction involving other sites I21.3 ST elevation (STEMI) myocardial infarction of unspecified site I21.4 Non-ST elevation (NSTEMI) myocardial infarction I21.9 Acute myocardial infarction, unspecified I21.A Other type of myocardial infarction I21.A9 Other myocardial infarction type

I22: Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction I22.0 Subsequent ST elevation (STEMI) myocardial infarction of anterior wall I22.1 Subsequent ST elevation (STEMI) myocardial infarction of inferior wall I22.2 Subsequent non-ST elevation (NSTEMI) myocardial infarction I22.8 Subsequent ST elevation (STEMI) myocardial infarction of other sites I22.9 Subsequent ST elevation (STEMI) myocardial infarction of unspecified sites

I23: Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period) I23.7 Postinfarction angina I23.8 Other current complications following acute myocardial infarction

Important Safety Information (cont'd) The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) (5% of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Section 3

Section 4

Table of contents

Section 1

Disorders of lipoprotein metabolism and other lipidemias,

4

1

transient cerebral ischemic attacks and related syndromes, and ischemic heart diseases (cont'd)

Ischemic heart diseases (cont'd)

I24: Other acute ischemic heart diseases I24.8 Other forms of acute ischemic heart disease I24.9 Acute ischemic heart disease, unspecified

I25: Chronic ischemic heart disease I25.10 Atherosclerotic heart disease of native coronary artery without angina pectoris I25.110 Atherosclerotic heart disease of native coronary artery with unstable angina pectoris I25.111 Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm I25.118 Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris I25.119 Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris I25.2 Old myocardial infarction I25.700 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris I25.701 Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm I25.708 Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris I25.709 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris I25.710 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris I25.711 Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm I25.718 Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris I25.719 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris I25.720 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris I25.721 Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm I25.728 Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris I25.729 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris I25.730 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris I25.731 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm I25.738 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris I25.739 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris I25.750 Atherosclerosis of native coronary artery of transplanted heart with unstable angina I25.751 Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm I25.758 Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris I25.759 Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris I25.760 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina I25.761 Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm I25.768 Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris I25.769 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris I25.790 Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris I25.791 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm I25.798 Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris I25.810 Atherosclerosis of coronary artery bypass graft(s) without angina pectoris I25.811 Atherosclerosis of native coronary artery of transplanted heart without angina pectoris I25.812 Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris I25.83 Coronary atherosclerosis due to lipid rich plaque I25.84 Coronary atherosclerosis due to calcified coronary artery lesion

Section 2

Section 3

Section 4

Important Safety Information (cont'd) The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Table of contents

Section 1

5

2

Cerebrovascular diseases

Cerebrovascular diseases

I63: Cerebral infarction I63.0 Cerebral infarction due to thrombosis of precerebral arteries I63.00 Cerebral infarction due to thrombosis of unspecified precerebral artery I63.01 Cerebral infarction due to thrombosis of vertebral artery I63.011 Cerebral infarction due to thrombosis of right vertebral artery I63.012 Cerebral infarction due to thrombosis of left vertebral artery I63.013 Cerebral infarction due to thrombosis of bilateral vertebral arteries I63.019 Cerebral infarction due to thrombosis of unspecified vertebral artery I63.02 Cerebral infarction due to thrombosis of basilar artery I63.03 Cerebral infarction due to thrombosis of carotid artery I63.031 Cerebral infarction due to thrombosis of right carotid artery I63.032 Cerebral infarction due to thrombosis of left carotid artery I63.033 Cerebral infarction due to thrombosis of bilateral carotid arteries I63.039 Cerebral infarction due to thrombosis of unspecified carotid artery I63.09 Cerebral infarction due to thrombosis of other precerebral artery I63.10 Cerebral infarction due to embolism of unspecified precerebral artery I63.111 Cerebral infarction due to embolism of right vertebral artery I63.112 Cerebral infarction due to embolism of left vertebral artery I63.113 Cerebral infarction due to embolism of bilateral vertebral arteries I63.119 Cerebral infarction due to embolism of unspecified vertebral artery I63.12 Cerebral infarction due to embolism of basilar artery I63.131 Cerebral infarction due to embolism of right carotid artery I63.132 Cerebral infarction due to embolism of left carotid artery I63.133 Cerebral infarction due to embolism of bilateral carotid arteries I63.139 Cerebral infarction due to embolism of unspecified carotid artery I63.19 Cerebral infarction due to embolism of other precerebral artery I63.2 Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries I63.20 Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries I63.21 Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries I63.211 Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery I63.212 Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery I63.213 Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries I63.219 Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries I63.22 Cerebral infarction due to unspecified occlusion or stenosis of basilar artery I63.23 Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries I63.231 Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries I63.232 Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries I63.233 Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries I63.239 Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries I63.29 Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries

Section 2

Section 3

Section 4

Important Safety Information (cont'd) In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Table of contents

Section 1

6

2

Cerebrovascular diseases (cont'd)

I63: Cerebral infarction (cont'd) I63.3 Cerebral infarction due to thrombosis of cerebral arteries I63.30 Cerebral infarction due to thrombosis of unspecified cerebral artery I63.31 Cerebral infarction due to thrombosis of middle cerebral artery I63.311 Cerebral infarction due to thrombosis of right middle cerebral artery I63.312 Cerebral infarction due to thrombosis of left middle cerebral artery I63.313 Cerebral infarction due to thrombosis of bilateral middle cerebral arteries I63.319 Cerebral infarction due to thrombosis of unspecified middle cerebral artery I63.32 Cerebral infarction due to thrombosis of anterior cerebral artery I63.321 Cerebral infarction due to thrombosis of right anterior cerebral artery I63.322 Cerebral infarction due to thrombosis of left anterior cerebral artery I63.323 Cerebral infarction due to thrombosis of bilateral anterior arteries I63.329 Cerebral infarction due to thrombosis of unspecified anterior cerebral artery I63.33 Cerebral infarction due to thrombosis of posterior cerebral artery I63.331 Cerebral infarction due to thrombosis of right posterior cerebral artery I63.332 Cerebral infarction due to thrombosis of left posterior cerebral artery I63.333 Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries I63.339 Cerebral infarction due to thrombosis of unspecified posterior cerebral artery I63.34 Cerebral infarction due to thrombosis of cerebellar artery I63.341 Cerebral infarction due to thrombosis of right cerebellar artery I63.342 Cerebral infarction due to thrombosis of left cerebellar artery I63.343 Cerebral infarction due to thrombosis of bilateral cerebellar arteries I63.349 Cerebral infarction due to thrombosis of unspecified cerebellar artery I63.39 Cerebral infarction due to thrombosis of other cerebral artery I63.40 Cerebral infarction due to embolism of unspecified cerebral artery I63.411 Cerebral infarction due to embolism of right middle cerebral artery I63.412 Cerebral infarction due to embolism of left middle cerebral artery I63.413 Cerebral infarction due to embolism of bilateral middle cerebral arteries I63.419 Cerebral infarction due to embolism of unspecified middle cerebral artery I63.421 Cerebral infarction due to embolism of right anterior cerebral artery I63.422 Cerebral infarction due to embolism of left anterior cerebral artery I63.423 Cerebral infarction due to embolism of bilateral anterior cerebral arteries I63.429 Cerebral infarction due to embolism of unspecified anterior cerebral artery I63.431 Cerebral infarction due to embolism of right posterior cerebral artery I63.432 Cerebral infarction due to embolism of left posterior cerebral artery I63.433 Cerebral infarction due to embolism of bilateral posterior cerebral arteries I63.439 Cerebral infarction due to embolism of unspecified posterior cerebral artery I63.441 Cerebral infarction due to embolism of right cerebellar artery I63.442 Cerebral infarction due to embolism of left cerebellar artery I63.443 Cerebral infarction due to embolism of bilateral cerebellar arteries I63.449 Cerebral infarction due to embolism of unspecified cerebellar artery I63.49 Cerebral infarction due to embolism of other cerebral artery

Section 2

Section 3

Section 4

Important Safety Information (cont'd) The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively). The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Table of contents

Section 1

7

2

Cerebrovascular diseases (cont'd)

I63: Cerebral infarction (cont'd) I63.50 Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery I63.511 Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery I63.512 Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery I63.513 Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries I63.519 Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery I63.52 Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery I63.521 Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery I63.522 Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery I63.523 Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries I63.529 Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery I63.53 Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery I63.531 Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery I63.532 Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery I63.533 Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries I63.539 Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery I63.54 Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery I63.541 Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery I63.542 Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery I63.543 Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries I63.549 Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery I63.59 Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery I63.6 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic I63.8 Other cerebral infarction I63.9 Cerebral infarction, unspecified

I65: Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction I65.0 Occlusion and stenosis of vertebral artery I65.01 Occlusion and stenosis of right vertebral artery I65.02 Occlusion and stenosis of left vertebral artery I65.03 Occlusion and stenosis of bilateral vertebral arteries I65.09 Occlusion and stenosis of unspecified vertebral artery I65.1 Occlusion and stenosis of basilar artery I65.2 Occlusion and stenosis of carotid artery I65.21 Occlusion and stenosis of right carotid artery I65.22 Occlusion and stenosis of left carotid artery I65.23 Occlusion and stenosis of bilateral carotid arteries I65.29 Occlusion and stenosis of unspecified carotid artery I65.8 Occlusion and stenosis of other precerebral arteries I65.9 Occlusion and stenosis of unspecified precerebral artery

Section 2

Section 3

Section 4

Important Safety Information (cont'd) In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download